Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

Mendus Q1: CEO Interview

By Jesper HagmanCommunity Manager
Mendus

Immunotherapy remains a game-changer in the rapidly evolving landscape of cancer treatment. Leading this wave of innovation is Mendus, which released its Q1 report yesterday (6/5). To discuss the report and key developments from the quarter, we spoke with CEO Erik Manting in an exclusive interview.

Watch the Q1 presentation from Mendus here. 

Följ oss på:

  • X (Twitter)
  • Instagram
  • TikTok

Du är hjärtligt välkommen att ansluta dig till vår kostnadsfria community och delta i heta aktiediskussioner på forumet

Stay up to date
Company management interviews

Recent videos

Beijer Ref, Audiocast, Q4'25
30.01.2026 klo 11.00 Beijer Ref
Lifco, Audiocast, Q4'25
30.01.2026 klo 10.00 Lifco
Enea, Audiocast, Q4'25
30.01.2026 klo 09.30 Enea
Hexpol, Audiocast, Q4'25
29.01.2026 klo 15.00 Hexpol
Intrum, Webcast, Q4'25
29.01.2026 klo 14.00 Intrum
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.